These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32402171)

  • 21. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
    Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
    N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity.
    Bartalena L; Marcocci C; Tanda ML; Marinò M
    J Endocrinol Invest; 2022 Aug; 45(8):1603-1604. PubMed ID: 35633498
    [No Abstract]   [Full Text] [Related]  

  • 23. Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists.
    Chern A; Dagi Glass LR; Gudis DA
    Otolaryngol Head Neck Surg; 2021 Dec; 165(6):757-758. PubMed ID: 33781112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Teprotumumab for Graves' orbitopathy and ototoxicity: moving problems from eyes to ears?
    Bartalena L; Marinò M; Marcocci C; Tanda ML
    J Endocrinol Invest; 2022 Jul; 45(7):1455-1457. PubMed ID: 35403994
    [No Abstract]   [Full Text] [Related]  

  • 25. Teprotumumab: A Review in Thyroid Eye Disease.
    Nie T; Lamb YN
    Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Teprotumumab for Thyroid Eye Disease.
    Hwang CJ; Eftekhari K
    Int Ophthalmol Clin; 2020; 60(2):47-55. PubMed ID: 32205652
    [No Abstract]   [Full Text] [Related]  

  • 27. Teprotumumab (Tepezza) for thyroid eye disease.
    Med Lett Drugs Ther; 2021 May; 63(1625):87-88. PubMed ID: 34101720
    [No Abstract]   [Full Text] [Related]  

  • 28. Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition.
    Smith TJ
    J Neuroophthalmol; 2020 Mar; 40(1):74-83. PubMed ID: 32040069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.
    Smith TJ
    Front Endocrinol (Lausanne); 2020; 11():610337. PubMed ID: 33391187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Teprotumumab: The First Approved Biologic for Thyroid Eye Disease.
    Hwang CJ; Eftekhari K
    Int Ophthalmol Clin; 2021 Apr; 61(2):53-61. PubMed ID: 33743528
    [No Abstract]   [Full Text] [Related]  

  • 31. Teprotumumab for Optic Neuropathy in Thyroid Eye Disease.
    Slentz DH; Smith TJ; Kim DS; Joseph SS
    JAMA Ophthalmol; 2021 Feb; 139(2):244-247. PubMed ID: 33270090
    [No Abstract]   [Full Text] [Related]  

  • 32. Rifle Blast Exacerbating Hearing Loss in a Patient Treated With Teprotumumab for Thyroid Eye Disease.
    Reed DS; Kostosky N; Davies BW; Epstein A; Durairaj VD
    Ophthalmic Plast Reconstr Surg; 2022 Mar-Apr 01; 38(2):e41-e43. PubMed ID: 34652314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The knowns and unknowns of teprotumumab for thyroid eye disease.
    Bednarczuk T; Pearce SH
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):323-325. PubMed ID: 33865499
    [No Abstract]   [Full Text] [Related]  

  • 34. Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease.
    Hoang TD; Nguyen NT; Chou E; Shakir MK
    BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 33972303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series.
    Chu M; Sung J; Song M; Song A; Song J
    J Med Case Rep; 2022 May; 16(1):195. PubMed ID: 35538553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New-Onset of Inflammatory Bowel Disease in a Patient Treated With Teprotumumab for Thyroid Associated Ophthalmopathy.
    Ashraf DC; Jankovic I; El-Nachef N; Winn BJ; Kim GE; Kersten RC
    Ophthalmic Plast Reconstr Surg; 2021 Sep-Oct 01; 37(5):e160-e164. PubMed ID: 33710035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Teprotumumab vs Intravenous Methylprednisolone for Thyroid Eye Disease: Is There Still a Role for Steroids?
    Campbell AA
    JAMA Ophthalmol; 2022 Apr; 140(4):335-336. PubMed ID: 35175298
    [No Abstract]   [Full Text] [Related]  

  • 38. A Prospective Study Examining Audiometry Outcomes Following Teprotumumab Treatment for Thyroid Eye Disease.
    Douglas RS; Parunakian E; Tolentino J; Malkhasyan E; Geng J; Sherman M; Ugradar S
    Thyroid; 2024 Jan; 34(1):134-137. PubMed ID: 37962269
    [No Abstract]   [Full Text] [Related]  

  • 39. Teprotumumab (Tepezza) for Thyroid Eye Disease.
    Couch SM
    Mo Med; 2022; 119(1):36-41. PubMed ID: 36033157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ototoxicity and Teprotumumab.
    Highland J; Gordon S; Reddy D; Patel N
    Ann Otol Rhinol Laryngol; 2022 Aug; 131(8):910-913. PubMed ID: 34448414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.